Publicaciones científicas

Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer

J. Cortés (1), J Rodríguez (1), J.A. Díaz-González (3), C. Garzón (1), A. Gúrpide (1), L. Arbea (1), I. Gil-Bazo (1), V. Navarro (1), M. Cambeiro (1), A.I. Nicolás (2), S. Martín-Algarra (1), J. García-Foncillas (1) and E. Calvo (4)
(1) Department of Oncology, Clínica Universitaria de Navarra, Avenida de Pío XII, 36, 31008 Pamplona, Spain;
(2) Department of Radiology, Clínica Universitaria de Navarra, Avenida de Pío XII, 36, 31008 Pamplona, Spain;
(3) Department of Oncology, Gregorio Marañón Hospital, 28007 Madrid, Spain;
(4) Department of Oncology, San Jaime Hospital, 03280 Torrevieja, Alicante, Spain

Revista: British Journal of Cancer

Fecha: 01/07/2002

Oncología Radioterápica Área del Cáncer de Pulmón Oncología Médica

Tumour response evaluation after chemotherapy has become crucial in the development of many drugs. In contrast to the standard bidimensional WHO criteria, the recently described Response Evaluation Criteria In Solid Tumors are based on unidimensional measurements.

The aim of the present study was to compare both methods in patients with metastatic non-small cell lung cancer. One hundred and sixty-four patients treated with two cisplatin-paclitaxel-based chemotherapy schedules between June 1994 and December 2000 were analysed. The measurements were reviewed by an independent panel of radiologists. Patient characteristics were: median age of 55 years (range 24-77 years) and a male to female ratio of 129 : 35.

Adenocarcinoma and squamous carcinoma were the most common histologies. Vinorelbine was the third drug used in 77 patients and gemcitabine in 87. The ratio unidimensional/bidimensional was as follows: response 85 : 85; stable disease 32 : 32; progression 47 : 42 and not assessable 0 : 5. Kappa for agreement between responders was 0.951 (95% CI: 0.795-1.0) (P<0.001). Both WHO criteria and Response Evaluation Criteria In Solid Tumors give similar results in assessing tumour response in patients with non-small cell lung cancer after chemotherapy.

The unidimensional measurement could replace the more complex bidimensional one.

CITA DEL ARTÍCULO  Br J Cancer. 2002 Jul 15;87(2):158-60

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra